MetaCap

Moleculin Biotech (MBRX) vs Optimi Health (OPTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Optimi Health is the larger company by market cap ($8.6 million vs $8.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBRX+1663.50%OPTH-62.62%
+2115%+974%-166%
Oct 7, 20261 yearNov 20, 2026
MBRX+1651.13%OPTH-62.44%
+1965%+903%-159%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBRX versus OPTH key metrics
MetricMBRXOPTH
Share price$7.74$1.51
Market cap$8.22M$8.65M
1-day change-2.40%-13.71%
P/E ratio (TTM)0.04—
EPS (TTM)$179.60$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-33.56M—
52-week high$202.50$6.40
52-week low$3.22$1.51
Distance from 52-week high-96.18%-76.41%
Analyst consensusstrong_buy—
Avg. price target upside+55.04%—
Average volume44.66K43.55K
Shares outstanding1.06M5.73M
Employees17—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About Optimi Health

OPTH stock →

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations

MBRX vs OPTH FAQ

Which is bigger, Moleculin Biotech or Optimi Health?

Optimi Health (OPTH) is larger, with a market capitalization of $8.65M compared with $8.22M for Moleculin Biotech (MBRX).

Are Moleculin Biotech and Optimi Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons